SynthesisThoracic cancer2018
P16
Synthesis in Thoracic cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- Hallmarks of the ageing lung: 10 years later.The European respiratory journal · 2026Review
- Epigenetic profiling of circulating cell-free DNA for early detection and minimal residual disease assessment in lung cancer: a focus on DNA methylation.Frontiers in oncology · 2026Review
- Cuproptosis in lung cancer: mechanisms and therapeutic potential.Molecular and cellular biochemistry · 2024Review
- Advancements in the clinical application of gene methylation for early cancer detection.Frontiers in epigenetics and epigenomics · 2024Review
- Bronchoalveolar Lavage Fluid-Isolated Biomarkers for the Diagnostic and Prognostic Assessment of Lung Cancer.Diagnostics (Basel, Switzerland) · 2022Review
- Article
- DNA Methylation Markers in Lung Cancer.Current genomics · 2021Review
- Comparison of Bisulfite Pyrosequencing and Methylation-Specific qPCR for Methylation Assessment.International journal of molecular sciences · 2020Article
- Loss of CDKN2A at chromosome 9 has a poor clinical prognosis and promotes lung cancer progression.Molecular genetics & genomic medicine · 2020Article
- Expression and role of p16 and GLUT1 in malignant diseases and lung cancer: A review.Thoracic cancer · 2020Review
- Epigenetic Silencing of LMX1A Contributes to Cancer Progression in Lung Cancer Cells.International journal of molecular sciences · 2020Article
- Promoter Methylation of Selected Genes in Non-Small-Cell Lung Cancer Patients and Cell Lines.International journal of molecular sciences · 2020Article
- Distal-type bronchiolar adenoma of the lung expressing p16Pathology international · 2020Review
- Expression of p16 and p53 in non-small-cell lung cancer: clinicopathological correlation and potential prognostic impact.Biomarkers in medicine · 2019Article
- Comparison of value of biomarkers in diagnosing lung cancer: An overview of systematic reviews protocol.Medicine · 2019Article
- A Diagnostic Panel of DNA Methylation Biomarkers for Lung Adenocarcinoma.Frontiers in oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis meta-analysis was conducted to investigate the diagnostic performance of P16
methodsTwo reviewers independently searched the Web of Science, PubMed, Cochrane, Embase, China National Knowledge Infrastructure, and Chinese Biomedical Literature databases. Publications relevant to P16
resultsTwenty-six publications with 1768 lung cancer cases and 1323 controls were included. The pooled sensitivity, specificity, positive and negative likelihood ratios, and diagnostic odds ratio were 0.46 (95% confidence interval [CI] 0.43-0.48), 0.90 (95% CI 0.88-0.91), 6.33 (95% CI 3.89-10.30), 0.57 (95% CI 0.50-0.65) and 10.72 (95% CI 6.94-16.56), respectively, for P16
conclusionP16
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.